REFILE-Allergy Therapeutics says study fails to find hay fever therapy dose range

June 27 (Reuters) - Drug developer Allergy Therapeutics Plc

said a study on suitable doses of its therapy to treat

grass allergic rhinitis, or hay fever, did not find a

recommended dose for a late-stage trial.

Read more